Search

Search Constraints

You searched for: Author/Creator Vitolo, U.

Search Results

2. BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2, AND TP53 IN UNTREATED POOR‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017)

3. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. (June 2017)

4. CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY. (June 2017)

5. CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST‐LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. (June 2017)

6. CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM‐PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET‐ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL). (June 2017)

7. END OF TREATMENT PET‐CT PREDICTS PROGRESSION‐FREE SURVIVAL IN DLBCL AFTER FIRST‐LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY. (June 2017)

9. HBV reactivation in pOBI is influenced by detectable viremia at baseline rather than duration of prophylaxis with lamivudine. Issue 1 (16th February 2017)

10. IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. (12th June 2019)